-
Potential CF Therapy PTI-428 Receives Orphan Drug Status in Europe
Proteostasis Therapeutics’ investigational CF therapy PTI-428 has been granted orphan drug designation by the European Commission. Click here to read more about it.
What are your thoughts about this news?
Sorry, there were no replies found.
Log in to reply.